> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# New-generation drug-eluting stents judged cost-effective over bare-metal stents in Taiwan
- URL: https://www.coios.me/new-generation-drug-eluting-stents-judged-cost-effective/
- Published: 2026-11-21T13:02:05.000Z
- Updated: 2026-11-21T16:38:09.000Z
- Description: In Taiwan, new-generation drug-eluting stents were linked to 43% lower five-year mortality after myocardial infarction, at NT$302,750 per death avoided.
- Author: Daniel Ryan
- Tags: Data, models and systems, Value in health, Taiwan, #peer-reviewed, #new, #item, #source-2026-11, #score-62

This study compared new-generation drug-eluting stents with bare-metal stents after myocardial infarction, from Taiwan's national health insurance perspective. It used all 10,672 patients stented in 2018, followed to 2023, and matched 3,913 per group by propensity score. Drug-eluting stents were linked to 52%, 48% and 43% lower 1-, 2- and 5-year mortality, and NT$27,839 higher 1-year cost. The incremental cost per death avoided was NT$463,983, NT$241,299 and NT$302,750 at 1, 2 and 5 years. Against the World Health Organization threshold, the authors judged these stents cost-effective. Effectiveness was counted as deaths avoided rather than quality-adjusted life years, and the abstract states no limitations.

*Why it is interesting: Drug-eluting stents are the preferred treatment for myocardial infarction, yet some national insurance systems do not reimburse them. This study prices their survival gain over five years in a whole national cohort.*

Source

[International Journal for Quality in Health Care, 19 November 2026](https://doi.org/10.1093/intqhc/mzag193?ref=coios.me)

Paper

Cost-effectiveness analysis of new-generation drug-eluting stents for myocardial infarction: a nationwide population-based study

Authors

Tung YC, Chang GM

DOI

10.1093/intqhc/mzag193

Type

Peer-reviewed article

Design

Nationwide propensity-matched cohort (10,672 MI patients, 3,913 per arm, 2018-2023) with Cox and linear regression and ICER calculation

Verdict

New finding

Driver

[Value in health](https://www.coios.me/d-health-economics/)